Results 71 to 80 of about 2,707 (157)

CRISPR Screening and Comparative LC‐MS Analysis Identify Genes Mediating Efficacy of Delamanid and Pretomanid against Mycobacterium tuberculosis

Advanced Science
Tuberculosis (TB), the leading cause of death from bacterial infections worldwide, results from infection with Mycobacterium tuberculosis (Mtb). The antitubercular agents delamanid (DLM) and pretomanid (PMD) are nitroimidazole prodrugs that require ...
Mei‐Yi Yan, Haifeng Li, Yun‐Mo Qu, Si‐Shang Li, Dandan Zheng, Xiao‐Peng Guo, Zhaojun Wu, Jie Lu, Yu Pang, Weimin Li, Jian Yang, Lingjun Zhan, Yi‐Cheng Sun   +12 more
doaj   +1 more source

Delamanid [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Evaluation of a short, all oral treatment regimen including bedaquiline, delamanid, linezolid, clofazimine, and pyrazinamide named “Regimen C” for pre-XDR tuberculosis in Niger

Frontiers in Tuberculosis
BackgroundThe emergence of extensively drug-resistant tuberculosis (XDR-TB) poses a serious challenge to global tuberculosis control, particularly in high-burden countries like Niger. In 2021, a new fully oral, shorter treatment regimen, named regimen C,
Soumana Boubacar Soumana, Abdourahamane Yacouba, Abdourahamane Yacouba, Cheikh Aboubacar Abdoul Lawi, Ibrahim Oumar, Bassirou Souleymane, Alphazazi Soumana, Tapha Ounoussa, Mahamadou Doutchi, Mamane Daou, Souleymane Brah, Souleymane Brah, Eric Adehossi, Saidou Mamadou, Saidou Mamadou   +14 more
doaj   +1 more source

Targeting the Heart of Mycobacterium: Advances in Anti-Tubercular Agents Disrupting Cell Wall Biosynthesis

Pharmaceuticals
Mycobacterium tuberculosis infections continue to pose a significant global health challenge, particularly due to the rise of multidrug-resistant strains, random mycobacterial mutations, and the complications associated with short-term antibiotic ...
Ahmad Diab, Henry Dickerson, Othman Al Musaimi   +2 more
doaj   +1 more source

Effectiveness of new antituberculosis drugs in the treatment of children and adolescents with chemoresistant tuberculosis

Infusion & Chemotherapy
BACKGROUND. There is a significant decrease the effectiveness of antituberculous (anti-TB) treatment on the background of multidrug and extensive drug resistance (MDR/XDR) of Mycobacterium tuberculosis.
M.І. Sakhelashvili, I.L. Рlatonova, O.I. Sakhelashvili-Вil   +2 more
doaj   +1 more source

Bedaquiline plus delamanid for XDR tuberculosis [PDF]

The Lancet Infectious Diseases, 2016
Marie, Lachâtre, Christophe, Rioux, Damien, Le Dû, Mathilde, Fréchet-Jachym, Nicolas, Veziris, Elisabeth, Bouvet, Yazdan, Yazdanpanah   +6 more
openaire   +2 more sources

Incidence and risk factors of adverse drug reactions in multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) regimens containing new drugs: a retrospective study of two national multicenter cohorts. [PDF]

J Thorac Dis
Wang Y, Fu L, Li Z, Liu Y, Li L.
europepmc   +1 more source

Therapeutic drug monitoring-guided treatment of XDR TB with an RpoB I491F mutation-a case report. [PDF]

JAC Antimicrob Resist
Klingmüller A, Zuber S, Hoffmann AM, Köhler N, Suárez I, Preßel T, Niemann S, Dreyer V, Decosterd LA, Choong E, Schütz B, Friesen I, Rybniker J.   +12 more
europepmc   +1 more source

Interim efficacy and safety analysis of the regimen containing delamanid in the treatment of multidrug resistant/rifampicin-resistant/extensively drug-resistant tuberculosis: a single-arm, prospective, monocentric, observational study. [PDF]

BMC Infect Dis
Qin Y, Chen Y, Cai Q.
europepmc   +1 more source

A Prospective Cohort Study on the Usage, Safety, and Efficacy of Delamanid in Patients With Pulmonary Multidrug-Resistant Tuberculosis in South Korea. [PDF]

Open Forum Infect Dis
Mok J, Seo H, Cho Y, Lee T, Kim SH, Park HK, Oh JY, Shim TS.   +7 more
europepmc   +1 more source